Sun. Apr 6th, 2025 3:00:15 AM

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 – News-Medical

Byadmin

Apr 1, 2025

By admin

Related Post

How Close Is Fully Closed-Loop Automated Insulin Delivery? – Medscape

Apr 6, 2025 admin

Federal funding cancellation threatens major diabetes study, Indiana researcher says – WFYI

Apr 6, 2025 admin

One-year outcomes of a digital twin intervention for type 2 diabetes: a retrospective real-world study – Nature

Apr 6, 2025 admin

Leave a Reply Cancel reply

You missed

How Close Is Fully Closed-Loop Automated Insulin Delivery? – Medscape

Apr 6, 2025 admin

Federal funding cancellation threatens major diabetes study, Indiana researcher says – WFYI

Apr 6, 2025 admin

One-year outcomes of a digital twin intervention for type 2 diabetes: a retrospective real-world study – Nature

Apr 6, 2025 admin

US Food and Drug Administration approves Cambridge-developed artificial pancreas – University of Cambridge

Apr 6, 2025 admin